MTHFD2 marks pemetrexed resistance in pulmonary adenocarcinoma with EGFR wild type
MTHFD2 expression is strongly associated with prognosis in LUAD patients, as well as with increased cellular proliferation and resistance to pemetrexed in LUAD patients with wild-type EGFR. These findings suggest that MTHFD2 could serve as a valuable biomarker for predicting treatment outcomes in LUAD. Further studies are needed to fully explore the clinical implications and potential combination therapies targeting MTHFD2 in LUAD.
Authors
- Hanibal Bohnenberger (ORCID: https://orcid.org/0000-0003-1038-1030)
- Sha Yao
- Omar Elakad (ORCID: https://orcid.org/0000-0002-2633-9550)
- Lingling Peng (ORCID: https://orcid.org/0000-0002-6711-6695)
- Xiaolin Yang (ORCID: https://orcid.org/0000-0002-5492-7931)
- Wen Yu
- Aneesa Altaf
Institutions
- Central South University (CN)
- Huazhong Agricultural University (CN)
- Changsha Central Hospital (CN)
- Universitätsmedizin Göttingen (DE)
- Xiangya Hospital Central South University (CN)
- University of Göttingen (DE)
- University of South China (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-04-20
- DOI
- https://doi.org/10.1007/s12672-025-02355-z
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04